Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

BACKGROUND: Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with peptide receptor radionuclide therapy (PRRT) shows a high objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Braat, Arthur J. A. T., Kwekkeboom, Dik J., Kam, Boen L. R., Teunissen, Jaap J. M., de Herder, Wouter W., Dreijerink, Koen M. A., van Rooij, Rob, Krijger, Gerard C., de Jong, Hugo W. A. M., van den Bosch, Maurice A. A. J., Lam, Marnix G. E. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003090/
https://www.ncbi.nlm.nih.gov/pubmed/29902988
http://dx.doi.org/10.1186/s12876-018-0817-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003090/
https://www.ncbi.nlm.nih.gov/pubmed/29902988
http://dx.doi.org/10.1186/s12876-018-0817-8

Ejemplares similares